Background and Purpose-Childhood intracerebral hemorrhage is mainly attributable to underlying brain arteriovenous malformations (bAVMs). Multimodal treatment options for bAVMs include microsurgery and embolization, allowing an immediate cure, and radiosurgery, entailing longer obliteration times. Follow-up data on pediatric ruptured bAVMs are scarce, making it difficult to assess the risk of subsequent intracerebral hemorrhage. Our aim was to assess the clinical and angiographic outcome and to analyze risk factors for rebleeding during and after combined treatment of pediatric bAVMs. Methods-A prospectively maintained database of children referred to our institution between January 1997 and October 2012 for bAVMs was retrospectively queried to identify all consecutive ruptured bAVMs treated by surgery, embolization, and radiosurgery. The impact of baseline clinical and bAVM characteristics on clinical outcome, rebleeding rate, annual bleeding rate, and bAVM obliteration was studied using univariate and multivariate Cox regression analysis. Results-One hundred six children with ruptured bAVMs were followed up for a total of 480.5 patient-years (mean, 4.5 years). Thirteen rebleeding events occurred, corresponding to an annual bleeding rate of 2.71±1.32%, significantly higher in the first year (3.88±1.39%) than thereafter (2.22±1.38%; P<0.001) and in the case of associated aneurysms (relative risk, 2.68; P=0.004) or any deep venous drainage (relative risk, 2.97; P=0.002), in univariate and multivariate analysis. Partial embolization was associated with a higher annual bleeding rate, whereas initial surgery for intracerebral hemorrhage evacuation was associated with a lower risk of rebleeding. Conclusions-Associated aneurysms and any deep venous drainage are independent risk factors for rebleeding in pediatric ruptured bAVMs. Immediate surgery or total embolization might be advantageous for children harboring such characteristics, whereas radiosurgery might be targeted at patients without such characteristics. (Stroke. 2014;45:1664-1671.)
S troke in children is relatively rare, and intracerebral hemorrhages (ICHs) account for half of all childhood strokes compared with <20% of adult strokes. 1 The majority of childhood ICHs are attributable to underlying ruptured brain arteriovenous malformations (bAVMs). 1 Previous analyses, mainly performed in adults, [2] [3] [4] have shown that presentation with ICH might be the most important risk factor for future bleeding from a bAVM. 5 If a bAVM had bled, there was a much higher risk of bleeding recurrence than if the malformation had been diagnosed for other reasons (headache, seizures, migraine-like attacks). Hence, aggressive management of ruptured bAVMs seems appropriate. Treatment options include surgery, stereotactic radiation (radiosurgery), endovascular embolization, or a combination of these. Although microsurgical removal or complete embolization may provide an immediate and safe cure for low Spetzler-Martin grade bAVMs, such treatments may carry a relatively higher risk of morbidity in high Spetzler-Martin grade bAVMs. 3 In cases with a large nidus and high-flow shunts, partial embolization is performed either to facilitate surgery or to reduce the bAVM size to make it more likely to respond to radiosurgery. Hence, therapy may be initiated with several sessions of embolization for a few months and may be completed by radiosurgery. Effects of the latter are delayed, and obliteration rarely occurs <2 or 3 years afterward. Moreover, thrombosis is not always achieved, as shown by published series in which obliteration rates were ≈70% to 80%. 6, 7 In total, complete obliteration of a bAVM may take several years. 3, 6 Studies on the outcome of ruptured bAVM after combined treatment in children are scarce; indeed, most studies have focused on unruptured or untreated bAVMs in adult cohorts. 5, 8, 9 Although recent studies have also included children, most of them either included small cohorts of children or referred to them as part of a larger survey. 10, 11 In addition, little is known about the risk of rebleeding during the ICH-to-obliteration delay.
Our aim was to assess the clinical and angiographic outcome and to analyze risk factors for rebleeding during and after combined treatment of pediatric bAVMs.
Patients and Methods
The study conformed to generally accepted scientific principles and the research ethics standards of our institution and was approved by the ethics committee (CPP Ile de France III). The article was prepared in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. 12 Our institutional review board waived the need for written informed consent from the participants.
Patient Selection
The population was nested within a longitudinal cohort of consecutive patients referred to our institution for ruptured and unruptured bAVMs between January 1997 and October 2012. The Necker AVM databank is a database collecting demographic, clinical, imaging, and treatment data on consecutive patients admitted to Necker Enfants Malades Hospital. This prospectively maintained database was retrospectively queried to identify all consecutive patients matching the following inclusion criteria: (1) ruptured brain AVM, as demonstrated on digital subtracted angiography (DSA), histology, or computed tomographic (CT) angiography; (2) surgery, embolization, radiosurgery, either alone or in combination; and (3) children between birth and 16 years of age.
Ruptured intracranial aneurysms, dural and pial arteriovenous fistulas, and vein of Galen-type malformations were excluded. Demographic and clinical data included at least age at presentation, sex, and Glasgow Coma Scale score. Clinical outcome was assessed postoperatively in-hospital and then during long-term follow-up using the King Outcome Scale for Childhood Head Injury (KOSCHI). 7, 8 The KOSCHI is a pediatric modification of the Glasgow Outcome Scale characterizing global functional status. The KOSCHI incorporates functional impairments plus periodic symptoms such as headaches and seizures. It scores 1 for death, 2 for vegetative state, 3a and 3b for severe disability (3a worse), 4a and 4b for moderate disability (4a worse), and 5a and 5b for good recovery (5b full recovery, no residual symptoms). 13 In our study, the KOSCHI was determined from history obtained by parental interview and neurological examination findings. Deficits were considered clinically significant for a KOSCHI score <5a. Rebleeding was defined as a new symptomatic ICH.
Imaging Data
ICH imaging data included location, size, and volume calculated as A×B×C/2 with A=maximum length (in cm), B=width perpendicular to A on the same head CT slice, and C=number of slices multiplied by slice thickness.
14 Based on the morphological bAVM characteristics obtained on DSA and CT angiography, 15 bAVMs were classified according to the 5-point Spetzler-Martin grading system 16 with its 3 elements: size (scored 1 for small size, 2 for medium size, and 3 for large size), drainage type (scored 1 for bAVM with any drainage into the internal, deep cerebral venous system), and location (scored 1 for bAVM in functionally important, ie, eloquent, brain regions). bAVM imaging data also included the presence of a venous ectasia and arterial aneurysm (proximal, nidal, or remote lesions), the latter defined on superselective microcatheterism on DSA. Imaging outcome included complete obliteration, residual bAVM, or recurrence of bAVM, based on serial MRI. When MRI was considered normal, DSA was systematically performed to confirm bAVM obliteration.
Treatment Modalities
In the event of ICH, children were referred to our department from other hospitals in the Ile de France region (population of 12 million). Except in cases requiring emergency ICH evacuation (Glasgow Coma Scale score <8, infratentorial ICH or ICH with mass effect), the treatment modality was chosen at a multidisciplinary meeting including neurosurgeons, an interventional neuroradiologist, and a neurologist. As a general rule, in children in good clinical condition where surgical ICH evacuation was not considered, the a priori treatment plan for the studied patients required combined endovascular and surgical therapy. In bAVMs where an intranidal or a flow aneurysm could be identified as the likely source of bleeding, the endovascular treatment was aimed primarily at eliminating this source from the circulation, followed by partial or complete obliteration of the nidus. In small-or intermediate-sized bAVMs without an obvious source of bleeding, we sought to obliterate the nidus completely by endovascular means. In large bAVMs, where complete endovascular obliteration is unlikely, we, however, primarily aimed at flow reduction and partial nidus obliteration. After clinical recovery, patients with incompletely obliterated AVMs were scheduled for additional radiosurgery or neurosurgery. All embolizations were performed using the same technique throughout the study period. Embolization was considered complete when the bAVM was no longer visible at the end of the session and at 6 months, and partial in the case of residual bAVM for whatever reason (preoperative, palliative, preradiosurgical, targeted, or in a failed cure attempt). In our center, radiosurgery was uncommon in patients <3 years of age and had a lesser role for children with larger and surgically or endovascularly accessible bAVMs. Stereotactic radiosurgery was considered as the first-line treatment, after endovascular elimination of weak points, for bAVMs in surgically inaccessible areas or with high operative risk, that is, brain stem or deep nuclei.
Statistical Analysis
Rebleeding rate was calculated in terms of patient-years of follow-up (number of hemorrhage events divided by years of patient followup). The impact of baseline clinical and bAVM characteristics on clinical outcome, rebleeding rate, annual bleeding rate, and bAVM obliteration was analyzed using univariate and multivariate estimates of hazard ratio, calculated according to the Cox proportional hazards models. The probability of rebleeding-free survival for aneurysm and any deep venous drainage was estimated by the Kaplan-Meier method. Average annual rates were calculated according to the formula 12[(1−I c ) 1 /n ], where I c equals the cumulative incidence rate at n years, obtained by the Kaplan-Meier method. A difference was regarded as statistically significant at P<0.05 or when the confidence intervals did not overlap. According to the number of pairwise comparisons of interest, type 1 error was adjusted by using the Bonferroni multiple comparison adjustment. 17 For example, α level of 0.05 divided by 17 comparisons yielded an adjusted α of 0.003; thus, statistical significance level was set at P=0.003. All variables with a significant association in the univariate analyses after Bonferroni adjustments were entered into a multiple logistic regression model using backward elimination procedures to analyze potential predictors of unfavorable outcome (KOSCHI <5a). The stepwise elimination process included variables with a significance level of P<0.05. The overall Spetzler-Martin score was not used in this analysis because its separate components were already included in the model. Statistical analysis was performed using SPSS version 20 software.
Results

Population
Between 1997 and 2012, a total of 106 pediatric ruptured bAVMs were identified. Baseline clinical presentation and bAVM characteristics are presented in Table 1 . During the same period, 30 pediatric patients with unruptured bAVMs were referred to our center and did not differ from the study population in terms of demographic and bAVM characteristics (data not shown). A wide range of ages at presentation was observed; however, the majority of patients presented during their first 12 years (72 of 106; 67.9%). Among 106 patients, 60 (56.6%) were referred from local hospitals, 32 from the emergency medical service (30.2%), and 14 from abroad (13.2%), with a median delay between onset of symptoms and hospitalization of 1, 0, and 16 days, respectively.
Initial coma was present in one third of patients (38 of 106), and approximately half of the patients had at least a neurological deficit (51 of 106). Mean ICH volume was 30.4 cm 3 . Intraventricular hemorrhage and hydrocephalus were present in 64 of 106 (60.3%) and 39 of 106 (36.8%) patients, respectively. Three patients had a pure intraventricular hemorrhage, and none had a pure subarachnoid hemorrhage. Deep location was encountered in 15.1%, and associated aneurysms were found in 35.8%. Most bAVMs measured <3 cm (Table 1) . Spetzler-Martin grade was assessed on DSA (n=80) or on CT angiography (n=26). In 13 patients, because of the initial clinical status, no vascular imaging was performed at admission, and patients were urgently moved to the surgical room in light of the results of a noncontrast brain CT scan performed in the local hospital before transfer (13 of 106; 12.3%). In these 13 patients, the Spetzler-Martin grade was determined after surgery, and the grade may, therefore, have been underestimated. The Spetzler-Martin grade was ≥3 in 56 of 106 patients (52.8%; Table 1 ).
Treatment
Median onset to treatment time was 3 days (interquartile range, 0-4 days). Forty-three of 106 patients (40.6%) were treated with surgery alone, 12 (11.3%) with embolization alone, 8 (7.5%) with radiosurgery alone, 23 (21.7%) with combined surgery and embolization, 16 (15.1%) with combined radiosurgery and embolization, and 4 (3.8%) with combined surgery and radiosurgery. ICH evacuation was performed in 59 of 106 (55.7%) patients. AVM resection was performed once in 60 patients (56.6%), twice in 6 patients (5.7%), and thrice in 2 patients (1.9%). Embolization was performed in 51 of 106 (48.1%) patients including 31 patients (29.2%) treated in 1 session and 20 patients (18.9%) treated multiple times (median, 2; range, 2-5 sessions).
Clinical Outcome
One hundred three patients were clinically followed up for a total of 480.5 patient-years (mean, 4.5 years; maximum, 13.6 years) and were followed up on angiographic imaging for a total of 314.5 AVM-years (mean, 3.0 years; maximum 13.1 years). Clinical outcome was as follows: good (KOSCHI 5) in 81 of 106 (76.4%) patients, mild disability (KOSCHI 4) in 14 (13.2%), severe disability (KOSCHI 3) in 4 (3.8%), vegetative state (KOSCHI 2) in 2 (1.89%), and death in 5 (4.71%). Three patients died during the first 4 days from refractory intracranial hypertension, despite ICH evacuation and osmotherapy in the intensive care unit. All 3 had a Glasgow Coma Scale score <8 at admission. Two patients died of rebleeding 4 and 12 years later.
Unfavorable clinical outcome (KOSCHI <5) was significantly associated with coma at initial presentation, ICH volume >30 cm 3 , hydrocephalus, Spetzler-Martin grade ≥3, and any deep venous drainage, but not with initial ICH evacuation, rebleeding, infratentorial location, or occlusion status at the end of the follow-up (Table 2) .
bAVM Occlusion Status
Among 103 surviving patients, the overall obliteration rate was 61.2% (n=63). Twenty-two patients (21.4%) were still waiting for obliteration <12 months after radiosurgery (n=7) or 13 to 36 months after radiosurgery (n=15). Among the 21 remaining patients, 3 had died, 13 patients were still being treated with iterative embolizations, and 4 were lost to follow-up. Incomplete AVM occlusion on the last DSA was independently associated with deep location, Spetzler-Martin grade ≥3, and when initial ICH evacuation was not performed ( 
Rebleeding
Thirteen cases of rebleeding occurred during the follow-up. The median time to rebleeding was 12 (range, 0-85) months, and the median time to a third bleeding, which occurred in 5 patients, was 16 (range, 1-147) months. Two of 103 patients (1.9%) died as a result of rebleeding, whereas 5 (4.9%) had significant functional impairment (KOSCHI <5).
In univariate survival analysis, any deep venous drainage (relative risk, 2.97; P=0.002) and associated aneurysms (relative risk, 2.68; P=0.004) were associated with a 
Discussion
The main goal of the treatment of pediatric ruptured bAVMs is to preserve neurological function, mainly by preventing secondary ICH. Therefore, understanding the efficacy of a multimodal therapeutic approach, especially related to the risk of rebleeding, is crucial. In a large, single-center cohort of pediatric ruptured bAVMs consecutively treated during the past 15 years with a combination of surgery, endovascular treatment, and radiosurgery, long-term outcome was favorable in more than three quarters of patients. The mortality rate was <5%, whereas one third of the patients were comatose at admission. The annual bleeding rate was within a range of 2% to 3%, higher during the first year, in patients with SpetzlerMartin grade ≥3, any deep venous drainage, or associated aneurysms.
Data on the follow-up of pediatric cohorts with ruptured bAVMs are scarce, making it difficult to determine the risk of rebleeding accurately during and after multimodal treatment. Instead of reflecting pure natural history, we chose not to remove from analysis partially treated lesions, because the risk of hemorrhage is present until complete bAVM obliteration 2, 8, 9, 18 and because the management of pediatric ruptured bAVMs often requires multiple interventions and different modalities of treatment, sometimes taking years before the lesion is completely obliterated. 10, 19, 20 We think that the inclusion of partially treated bAVMs provides useful and closeto-the-real-world information because these are a relatively common occurrence in any center treating pediatric cerebrovascular disease, and these also allowed us to analyze the impact of partial treatment.
Our results confirm and extend previous retrospective, observational studies in adults that estimated the general risk of spontaneous bleeding to be within the range of 2% to 6% per year, 9,21-23 and probably higher in the first year. 5, 24 Taken together, the evidence seems to indicate that treatment, if decided on, would be more appropriate sooner rather than later, especially for pediatric patients presenting with ICH.
Our data indicate that in cases of pediatric ruptured brain AVMs, any deep venous drainage and associated aneurysm raise the risk for future bAVM hemorrhage, in line with adult cohorts. 5, 9, 25 In our cohort, brain AVMs with associated aneurysms represented 35.8% of the patients and had a higher annual bleeding rate. The reported rate of aneurysms associated with bAVMs varies widely (2.7%-58%) in the literature, depending on the definition of what constitutes an associated aneurysm, type of angiography used (selective versus superselective), and referral patterns. 9, 26, 27 The higher risk of rebleeding in bAVM with associated aneurysm remained elevated even after an initial partial treatment targeting endovascular occlusion of aneurysms. This may suggest that angioarchitectural detrimental characteristics such as associated aneurysms might herald a more severe intracranial vasculopathy with increased risk of hemorrhage, and perhaps more aggressive interventions, that is, embolization or surgery rather than radiosurgery for immediate cure, are justified. 3, 9 The practical implication is that intervention, if warranted, should commence sooner rather than later after diagnosis of ruptured bAVMs with any deep venous drainage or associated aneurysms.
A potentially disturbing finding for endovascular therapists is that the rebleeding risk was increased in children who underwent partial bAVM embolization. Thirty-eight of 103 patients underwent partial embolization, for various reasons (presurgical occlusion of deep feeders or weak points, decreased nidus size before radiosurgery, failed cure attempt, or, mainly, treatment of weak points such as aneurysms). Their annual bleeding risk was 4.69%, as compared with 1.64% per year for AVMs not submitted to partial embolization (complete embolization or surgery). This result shows that partial embolization may actually increase the risk of hemorrhage when used to treat target points of the bAVM. The results of this subgroup analysis should be interpreted with care because the sample was small, and the majority of cases were target embolization of nidal aneurysms. Associated aneurysms may herald a more severe vasculopathy with increased risk of ICH, and therefore comparison would not be appropriate, and perhaps more aggressive interventions are justified. Nevertheless, considering the whole cohort, we found no evidence that partial embolization reduced future hemorrhage risk from a pediatric brain AVM. These results, in line with others, 9 should not alter the fundamental role of endovascular therapy in the management of bAVMs, especially as surgical and radiosurgical adjuvants.
Although we consider microsurgical resection or complete embolization as the treatment of choice for ruptured bAVMs that can be treated safely, radiosurgery was performed in one quarter of our patients, in the case of nidus located in critical cortical areas or deep brain locations and brain stem. An important difference when comparing outcomes of surgery or embolization and radiosurgery for bAVMs is that patients remain at risk for hemorrhage after radiosurgery until the bAVM has gone on to complete obliteration. [28] [29] [30] In addition, concerns about the not-yet-fully-defined long-term toxicity of radiation to the developing nervous system delayed the widespread use of radiosurgery as a first-line treatment option for ruptured bAVMs in children. 
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Our study did not find children with multiple bAVMs. Willinsky et al 31 described multiple bAVMs in 9% of cases, notably because of a higher rate of underlying genetic disease, such as hereditary hemorrhagic telangectasia or WyburnMason syndrome in pediatric populations. In our study, the incidence of multiple bAVMs is likely to have been underestimated because of the failure to recognize microarteriovenous malformations associated with larger bAVM, particularly in patients with surgical treatment.
We found 1 case of AVM recurrence, 9 years after a complete surgical treatment, confirmed by DSA. Several studies have found recurrence rates of pediatric brain AVM within the range of 1.9% to 12.8%, 10, 11, 32 with normal DSA to recurrence delay of 3 months to 16 years. A recurrence at 3 months is unlikely to be a true recurrence; the previous angiographic cure may be explained by a hidden compartment of the bAVM, which is unfilled during nonselective angiography, a mere consequence of a mass effect from an ICH or injured brain on a small nidus. In contrast, later true recurrences may be explained by a potential for proliferation in the immature microvessel network, as supported by the detection of endothelial progenitor markers (CD31, CD34, and CD105) in resected AVM. 33 Age was recognized as a major risk factor for bAVM recurrence, with a 63% recurrence rate at 10 years for patients <20 years of age. 34 Therefore, a long-term imaging follow-up is recommended in pediatric AVM.
Our study has several limitations. First, there was a selection bias in our center, with a 78% rate of ruptured bAVMs (106 of 136 bAVM patients) as compared with a 55% rate in larger, adult studies. 18 This is explained by the fact that our center is an on-call emergency pediatric neurosurgical center. Second, despite our efforts to locate them, 4 patients were lost to follow-up; consequently, we might have underestimated the rebleeding rate. Third, because of the initial clinical status, no vascular imaging was performed at admission in 13 patients who underwent emergency ICH evacuation; thus, these patients might have been misclassified according to the Spetzler-Martin grading system. In addition, the angioarchitecture of bAVMs was based on the morphological characteristics obtained on initial DSA and CT angiography, before treatment was performed with a median onset to treatment time of 3 days. Consequently, we acknowledge that the precise vascular architecture of the bAVMs included in our study might have been compressed by the ICH, and Spetzler-Martin grades might have been underestimated because of the partial obliteration of the nidus. However, in terms of management strategies, many studies have demonstrated that the practical distinctions between grade 1 and 2 AVMs and between grade 4 and 5 lesions are of limited interest, 35 and many centers actually condensed the breakdown of bAVMs from 5 tiers to 3 tiers, because the 3-tier system retains a capability of predicting poor neurological outcomes that is equivalent to that of the 5-tier system. Fourth, our inclusion period was as long as 15 years, and evaluation and management may have changed during the inclusion period. Nonetheless, adjusting our analysis for year of ascertainment did not affect our conclusions. In addition, the treatment algorithm in our center was not modified during the study period, with an a priori treatment plan requiring embolization aiming at obliteration of the bleeding source if identified and at facilitating neurosurgery or radiosurgery without the primary goal of AVM occlusion by embolization alone. Finally, all embolizations were performed using coils or N-butyl cyanoacrylate. The use of ethylene-vinyl alcohol copolymer dissolved in dimethyl sulfoxide, now commercially available as Onyx (ev3, Irvine, CA), is US Food and Drug Administration-approved for embolization of bAVMs. Onyx has several advantages compared with N-butyl cyanoacrylate and is now routinely used in many pediatric centers 36 and for the past 12 months in our center. More studies on the use of Onyx with longer follow-up are certainly needed to confirm both its long-term safety and efficacy in this set of patients still undergoing growth and development.
Conclusions
Our results show that in pediatric ruptured bAVMs, the outcome was favorable in three quarters of patients. Spetzler-Martin grade ≥3, presence of associated aneurysms, and any deep venous drainage were independent risk factors for rebleeding from bAVMs. This information should be taken into consideration when deciding among the therapeutic options, and more effective means in the short term (surgery or total embolization) might be advantageous for patients harboring high-risk lesions. However, therapeutic approaches that entail longer obliteration times might be targeted at patients having a lower risk for rebleeding.
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